Innovation Report

Stephan Emmerth

Stephan Emmerth

PhD | Business Development Senior Manager BaseLaunch


Tel. +41 61 295 50 17

stephan.notexisting@nodomain.comemmerth@baselaunch.notexisting@nodomain.comch
report Life Sciences

10.11.2017

Myovant drug performs well in study

Basel – The Basel-based pharmaceutical company Myovant Sciences has announced positive results from a study evaluating relugolix. The drug performed well in efficacy and safety for the treatment of uterine fibroids.

Relugolix was evaluated in a phase 3 study for the treatment of pain associated with uterine fibroids. Myovant announced that 57.6 per cent of the women treated with relugolix experienced an improvement in their pain symptoms, compared to only 3.1 per cent of the patients in the placebo-controlled group.

Another phase 3 study evaluated the drug’s efficacy with regard to high menstrual blood loss associated with uterine fibroids.   

"Treatment with relugolix significantly decreased heavy menstrual bleeding and now pain associated with uterine fibroids, with the majority of women in the current study experiencing little or no pain by the end of the 12-week study," commented Juan Camilo Arjona Ferreira, chief medical officer of Myovant Sciences, in the statement.

Both studies were conducted by Takeda Pharmaceutical Company and the results will be submitted to regulatory authorities in Japan. Myovant Sciences is conducting its own phase 3 study for approval in the USA. 

Myovant Sciences is a subsidiary of Roivant Sciences, which was assisted by BaselArea.swiss in relocating its headquarters to Basel. Myovant Sciences presented positive study results for other relugolix applications in recent months. For instance, patients with endometriosis and those with prostrate cancer have been successfully treated with the drug. It lowers oestrogen levels in women and testosterone levels in men.